Overview
Reduces cytokine-induced inflammation while upregulating growth factors for extracellular matrix repair.
Proposed mechanism
Palmitoyl tetrapeptide-7 is a lipophilic analog of tetrapeptide-7 (Rigin) with enhanced penetration, mimicking SPARC's ECM-modulating activity.
What the evidence supports
Human data exists but the trials are small, short-term, or not yet replicated.
Graded Human-limited
Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Palmitoyl tetrapeptide-7 study
· DOI:10.1111/j.1468-2494.2005.00245.x · 2005
- [2]
Palmitoyl tetrapeptide-7 study (2005)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.